Grünenthal GmbH has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Acurex Biosciences Corp. has divulged fused quinone compounds acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.

Deciphera Pharmaceuticals LLC has identified phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3; Vps34) inhibitors reported to be useful for the treatment of cancer.

Alterome Therapeutics Inc. has synthesized RAC-α serine/threonine-protein kinase (AKT1; PKB α) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.

Beijing Konruns Pharmaceutical Co. Ltd. has disclosed tyrosine-protein kinase yes (YES1) inhibitors reported to be useful for the treatment of cancer.

Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

Ensem Therapeutics has divulged compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.

Eikon Therapeutics Inc. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and respiratory disorders.